BioNexus Gene Lab Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
BGLC$0.89+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM FINANCIAL STATEMENTS:1
AS OF DECEMBER 31, 2023 AND 2022
| As of | |||
|---|---|---|---|
| December 31, · December 31, | |||
| Note | 2023 | 2022 | |
| STOCKHOLDERS’ EQUITY | |||
| As at December 31, 2023, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 14,476,513 shares outstanding, and preferred stock, no par value 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*. | 10 | $17,191,315 | $10,929,574 |
| Additional paid in capital | (5,011,891) | (5,011,891) | |
| Accumulated surplus | (1,844,278) | 1,156,392 | |
| Accumulated other comprehensive losses | (677,294) | (409,062) | |
| TOTAL STOCKHOLDERS’ EQUITY | 9,657,852 | 6,665,013 | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $11,399,793 | $8,740,162 | |
- Issued and outstanding shares of common stock have been adjusted for the periods prior to July 20, 2023, to reflect the 12-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 10.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.